Federal Grant Award Summary

Brigham & Women's Hospital Inc. received a $891,382 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective May 15, 2026, with a completion date of February 28, 2031. This research initiative delivers a comprehensive, real-world evaluation of continuous glucose monitoring (CGM) technology in older adults with Type 2 diabetes across two large healthcare systems: Mass General Brigham and the University of California. The study evaluates how CGM-derived metrics influence clinician decision-making, compares clinical outcomes and care processes between CGM users and non-users across different age groups, and identifies structural and multilevel factors affecting CGM adoption among seniors.

The research generates three primary deliverables through a structure-process-outcome framework: (1) quantitative analysis using mixed-effect models and trajectory modeling to identify glycemic phenotypes linked to treatment decisions; (2) comparative effectiveness data on health outcomes including hemoglobin A1c, blood pressure, LDL cholesterol, weight, and hypoglycemia rates; and (3) implementation science findings using the Consolidated Framework for Implementation Research and rapid ethnography to identify system-level levers for improving CGM adoption. This work addresses critical gaps in understanding therapeutic inertia and real-world effectiveness of CGM technology in a vulnerable population experiencing disproportionate burden of Type 2 diabetes complications.